Biomedical subjects
Publications and source records attributed to H Behnke.
Explore the source record for details and available documents.
Toxic-shock-syndrome (TSS) is an acute febrile, exanthematous illness caused by toxins such as toxic-shock-syndrome-toxine-1 (TSST-1) and other endotoxines from staphylococcus aureus with an incidence of 0,5 per 100.000 inhabitants. Patients with menstrual toxic-shock-syndrome (menstrual-TSS) usually have TSS associated with menstruation and use of a vaginal device such as tampons. Other patients with non-menstrual toxic-shock-syndrome (non-menstrual-TSS) have a focus of staphylococcal infection such as a surgical wound infection or soft tissue abscess. TSS usually presents with fever, pharyngitis, diarrhoea, vomiting, myalgia and may progress rapidly (within hours) to signs of hypovolaemic hypotension and shock. In some cases TSS is associated with multisystem failure including shock, renal failure, myocardial failure and adult respiratory distress syndrome. In its acute phase the diagnosis of TSS is often uncertain because of its initial symptoms are non-specific and numerous conditions need to be considered in the differential diagnosis. But obviously less incidence, the signs and symptoms of toxic-shock-syndrome should be recognised early to permit successful therapy. The site of infection should be adequately drained and treated with antimicrobial therapy. Possible complications including ARDS and myocardial failure require a thorough understanding of its underlying pathophysiology to ensure appropriate intensive-care treatment. Only if appropriate therapy is instituted as early as possible, most of patients will be able to survive their toxic-shock-syndrome. In other cases TSS can be a rapidly progressive and perhaps lethal ending disease because of possible multiple organe failure such as ARDS.
OBJECTIVE: Lately introduced cardiosurgical procedures such as MIDCAB enable an early extubation immediately after surgery. This also requires an adequate anesthesia regime and especially a sufficient postoperative analgesia. Patient controlled analgesia (PCA) and intercostal nerve blockade (ICB) were evaluated for their suitability for postoperative pain relief in patients undergoing a MIDCAB procedure. MATERIAL AND METHODS: After approval by the local ethic committee and obtaining written informed consent 43 patients were included in this study. Anesthesia was induced and maintained in a total intravenous standardised manner with propofol, remifentanil, cisatracurium and additionally glyceroltrinitrate, clonidine and esmolol were given as needed. After revascularisation patients were randomly assigned to one of two groups receiving either 7.5 mg piritramid i.v. before extubation and continuing a PCA with 2 mg boli and a 10 min lockout, or an ICB with ropivacaine 1% (4 times 5 ml). Additionally all patients received 1 g paracetamol rectally before induction of anesthesia and 1 g metamizol i.v. at the end of surgery. A rescue medication of 3.75 mg piritramid i.v. was allowed. A pain score (NRS 0-10), the Aldrete score (AS 0-12) and oxygen saturation were obtained 1, 4, and 8 h after extubation. RESULTS: The ICB group showed a significantly greater pain reduction in the first (5.8 +/- 1.8 vs. 7.3 +/- 1.9; P < 0.02) and fourth h (3.6 +/- 1.3 vs. 4.6 +/- 1.4; P < 0.02), respectively. Transfer to an intermediate care ward one hr after extubation was achieved more often in the ICB group according to the AS (ICB 9.6 +/- 1.5 vs. PCA 8.9 +/- 1.2; P < 0.05), too. There was no difference with respect to the oxygen saturation. The additional piritramid demand was 9.3 mg in the ICP group and 5 mg in the PCA group in the first 8 hours postoperative. CONCLUSION: ICB gives a better pain relief in the early postoperative phase after MIDCAB procedures compared to a PCA. Both regimes are adequate in order to provide a sufficient pain relief and help to avoid prolonged postoperative mechanical ventilation. These will enable an early transfer of patients to an intermediate care station and save ICU capacity.
In obstetric anaesthesia almost all anaesthetic agents are capable of traversing the fetomaternal blood barrier. They all carry potential side-effects putting the unborn or newborn child at risk. Of major relevance is their potential for embryotoxicity, teratogenicity, postpartal cardiorespiratory or neuromuscular depression and the disturbance of thermoregulation. This can possibly lead to fetal malformation, asphyxia or floppy infant syndrome. Furthermore compromisation of uterine blood flow or contractility of the mature uterus plays an important role for the incidence of intrauterine asphyxia and premature labour or birth. Considering the physiological and pathophysiological alterations during pregnancy regarding all organ systems, the overall goal is to find an ideal choice of anaesthetic drugs and techniques in order to minimise an increased anaesthetic risk during pregnancy.
BACKGROUND: Absorption of local anaesthetics following intercostal blocks is rapid. Therefore, plasma concentrations of ropivacaine during intercostal blocks with ropivacaine 2, 5, 7.5 and 10 mg ml-1 (ropivacaine 5 ml injected into each of four intercostal spaces) in patients undergoing video-assisted thoracic surgery were determined. METHODS: After informed consent and ethics committee approval, 64 patients were randomly allocated to four groups for intercostal nerve block (ropivacaine 2, 5, 7.5 or 10 mg ml-1 at the end of surgery). Central (mixed) venous and arterial plasma samples were collected before the start of intercostal application, and 2, 5, 10, 15, 20, 30, 45, 60 and 90 min afterwards. Plasma concentrations of ropivacaine were measured by high performance liquid chromatography. RESULTS: Maximum venous plasma concentrations occurred after the mean times of 10.7 (range, 5-15), 10.8 (5-20), 11.3 (5-20) and 12.2 (5-45) min, respectively for each group. The groups had mean concentrations of 1.3 (SD, 0.6; range, 0.3-2.3), 2.1 (1.0; 0.5-4.5), 2.4 (1.0; 1.2-5.1) and 2.5 (0.9; 1.7-5.6) micrograms ml-1, respectively. Maximum arterial plasma concentration following 1.0% ropivacaine occurred after 16 (5-45) min with a mean of 2.3 (0.6; 1.5-3.6) micrograms ml-1. No signs of central nervous system or cardiac toxicity were observed. CONCLUSIONS: After intercostal blocks the absorption of ropivacaine is rapid compared with other techniques for regional anaesthesia and results in relatively high venous and arterial plasma concentrations, especially if a dose of 100 mg or more is used.
This study evaluates the pharmacokinetics of ropivacaine in children after caudal epidural injection. Twenty male children undergoing inguinal hernia repair were enrolled after ethics committee approval and informed parental consent, and were grouped according to age (10 'infants' aged less than 1 year and 10 'toddlers' aged 1-5 years). After induction of general anaesthesia, caudal epidural injection using ropivacaine 0.2% 1 ml.kg-1 was performed. Plasma concentrations of ropivacaine in the first 2 h after injection were determined by reversed-phase high-pressure liquid chromatography. Caudal blockade with ropivacaine 2 mg.ml-1 resulted in mean (SD) peak plasma concentrations of 0.73 [0.27] microg.ml-1 in infants and 0.49 [0.21] microg.ml-1 in toddlers (p < 0.01). Maximum plasma concentrations occurred after a median [range] period of 60 [15-90] min and 52.5 [30-120] min in infants and toddlers, respectively. Two infants (weighing 3.8 and 5.0 kg) showed the highest individual maximum plasma concentrations: 1.31 and 1.11 microg.ml-1. No clinical signs of local anaesthetic toxicity were observed. The results of the present investigation suggest that, from a pharmacokinetic point of view, caudal blockade using ropivacaine 0. 2% 1 ml.kg-1 can be regarded as a safe technique in children, i.e. in infants as well as in toddlers.
UNLABELLED: The aim of our study was to evaluate the pharmacokinetics and pharmacodynamics of ropivacaine in ilioinguinal-iliohypogastric blocks (IIB). After ethics committee approval and informed consent, 80 male adults scheduled for inguinal hernia repair were enrolled and randomized into four groups. After induction of general anesthesia, an IIB was performed double blinded in Groups 1, 2, and 3 with 0.25 mL/kg ropivacaine 2 mg/mL, 5 mg/mL, or 7.5 mg/mL and with saline in the Control group. Plasma concentration of ropivacaine was determined in venous blood using reversed-phase high-performance liquid chromatography. IIB with ropivacaine resulted in peak plasma concentrations of 0.3+/-0.15 microg/mL (Group 1) (mean +/- SD), 0.75+/-0.45 microg/mL (Group 2), or 1.57+/-0.82 microg/mL (Group 3). These concentrations occurred after 30 (15-60) min, median (range), 30 (10-60) min, and 45 (15-60) min, in the respective groups. Three of 19 patients in Group 1, 6 of 18 in Group 2, and 5 of 20 in Group 3 did not need any additional analgesics within 24 h postoperatively, but all 20 control patients did. Time to the first demand for analgesia was significantly shorter in the Control group (median 0.3 h [range 0-2.8]) compared with 1.5 h (0.5-24 h), 2 h (0.5-24 h), and 2 h (1.0-24 h) in Groups 1, 2, and 3, respectively. Three patients in Group 3 had a postoperative motor block of the femoral nerve. In conclusion, a ropivacaine dose of 0.25 mL/kg of 5 mg/mL seems adequate for IIB accompanying general anesthesia for postoperative pain relief. However, the pharmacokinetic results obtained suggest that even larger doses (0.25 mL/kg of 7.5 mg/mL ropivacaine) for IIB do not result in plasma concentrations in a toxic range. IMPLICATIONS: Ropivacaine, a new local anesthetic, proved to be effective for pain relief after hernia repair in ilioinguinal blocks accompanying general anesthesia. Plasma concentrations peaked after 30-45 min, and were within safe limits after application of 0.25 mL/kg of 2, 5, or 7.5 mg/mL ropivacaine.
The serostatus of hepatitis C in pediatric oncological patients and in individuals on renal replacement therapy was tested for circulating antibodies to the c100-3 recombinant antigen of hepatitis C. Upon prescreening, 12 of 82 patients in the pediatric oncological group, 6 of 108 renal transplant recipients, and 17 of 150 patients on chronic intermittent hemodialysis were repeatedly positive. Further testing of these 35 sera by supplemental test assays revealed conflicting data, mostly in the pediatric oncological group and in renal transplant recipients. Only in 10 sera were identical results obtained, suggesting that positive test results in some groups at risk have only a low predictive value.
A mentally retarded female with aniridia, microcephaly and no other major malformations has been studied using G-banded prometaphase chromosomes. This study revealed a reciprocal translocation of chromosome 8 and chromosome 11 with one break point in 8q and two breakpoints in 11p. An interstitial segment of 11p is lost. Both parents have a normal karyotype. The importance of chromosome analyses of patients with aniridia and mental retardation is discussed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.